Fear of missing out: Drug availability in the United States vs Canada

Background
Per capita spending on drugs in the United States is double that of Canada. One commonly debated point when comparing the 2 countries is whether this additional spending allows residents of the United States access to valuable therapies not available in Canada.

Objective
This study examines the therapeutic value of prescription drugs used in the United States that are not marketed in Canada.

Methods
This cross-sectional study used IQVIA Multinational Integrated Data Analysis System data to identify drugs purchased in the United States but not in Canada from 2017 to 2021. 

Results
2,084 products were purchased in the United States but not in Canada from 2017 to 2021; 1,685 were excluded because they were not prescription drugs, were combinations in which each active pharmaceutical ingredient was already available in the United States as a separate drug, had been discontinued in the United States by August 30, 2023, or were marketed in Canada by August 30, 2023.


Conclusion
There was similar access to important prescription drug therapies in the United States and Canada. Overall, the additional spending in the United States may not have necessarily translated into access to important therapeutic innovations.

Citation
Tadrous M,  Chen C, Callaway Kim K, Ho M, Lexchin J, Hernandez I, Suda K. (2024). Fear of missing out: Drug availability in the United States vs Canada. JMCP.

Access the full article:


Date Released: November 29, 2024

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.